LINC-ROR and prostate carcinoma: Jiang et al. discovered that lincROR interacts with and stabilizes MYH9, enhancing the β-conjugated protein/HIF1α pathway, creating a positive feedback loop of lincROR/MYH9/HIF1α, and thus, promoting Docetaxel resistance in prostate cancer (Jiang et al., 2023).